How much revenue does Sienna Biopharmaceuticals make?

Sienna Biopharmaceuticals reported $0 in revenue for fiscal year 2018. In Q3 2019 revenue was $0.

What companies are similar to Sienna Biopharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Rebus Holdings, Inc. (RBSH), Curative Biosciences, Inc. (CBDX), Hemagen Diagnostics, Inc. (HMGN), Comera Life Sciences Holdings, Inc. (CMRA).

Sienna Biopharmaceuticals, Inc. (SNNAQ) Stock

About Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical t...

At a glance

Sienna Biopharmaceuticals reported revenue of $0 for fiscal year 2018, and net income of -$73.47 million. In Q3 2019 (the quarter ended September 30, 2019) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2018.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.